This may also explain why tilsotolimod in combination with ipilimumab (anti–CTLA‐4) did not improve ORR or OS in a phase 3 trial in advanced PD‐1 blockade–resistant melanoma.29 This evidence concerns the gene PDCD1 and melanoma.